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ABSTRACT
Introduction: Exposure to secondhand smoke (SHS)
increases children’s risk of acquiring chest and ear
infections, tuberculosis, meningitis and asthma.
Smoking bans in public places (where implemented)
have significantly reduced adults’ exposure to SHS.
However, for children, homes remain the most likely
place for them to be exposed to SHS. Additional
measures are therefore required to protect children
from SHS. In a feasibility study in Dhaka, Bangladesh,
we have shown that a school-based smoke-free
intervention (SFI) was successful in encouraging
children to negotiate and implement smoking
restrictions in homes. We will now conduct a pilot trial
to inform plans to undertake a cluster randomised
controlled trial (RCT) investigating the effectiveness
and cost-effectiveness of SFI in reducing children’s
exposure to SHS.
Methods and analysis: We plan to recruit 12
primary schools in Dhaka, Bangladesh. From these
schools, we will recruit approximately 360
schoolchildren in year 5 (10–12 years old), that is, 30
per school. SFI consists of six interactive educational
activities aimed at increasing pupils’ knowledge about
SHS and related harms, motivating them to act,
providing skills to negotiate with adults to persuade
them not to smoke inside homes and helping families
to ‘sign-up’ to a voluntary contract to make their
homes smoke-free. Children in the control arm will
receive the usual education. We will estimate:
recruitment and attrition rates, acceptability, fidelity to
SFI, effect size, intracluster correlation coefficient, cost
of intervention and adverse events. Our primary
outcome will consist of SHS exposure in children
measured by salivary cotinine. Secondary outcomes
will include respiratory symptoms, lung function tests,
healthcare contacts, school attendance, smoking
uptake, quality of life and academic performance.
Ethics and dissemination: The trial has received
ethics approval from the Research Governance
Committee at the University of York. Findings will help
us plan for the definitive trial.
Trial registration number: ISRCTN68690577.
INTRODUCTION
Secondhand smoke (SHS) contains an esti-
mated 4000 toxic chemicals and is a serious
health hazard to non-smokers. Every year, an
estimated 600 000 people die due to SHS
exposure.1 Exposure to SHS is particularly
harmful to children’s health and increases
their risk of acquiring lower respiratory tract
and middle ear infections,2–4 invasive menin-
gococcal disease,5 tuberculosis6 7 and inci-
dent cases, recurrent episodes and increased
severity of asthma.8 Parental smoking is also
associated with their children’s admissions
to hospitals.3 Children living in smoking
households are at risk of poor general and
functional health,9 lower academic perform-
ance,10 and a high smoking uptake in later
life.11
Recognising SHS as a public health threat,
most countries have introduced comprehen-
sive smoking bans in enclosed public and
workplaces. This has, in countries where
these bans are strictly enforced, signiﬁcantly
Strengths and limitations of this study
▪ A pilot to inform the parameters required for a
pioneering trial to test the effectiveness and cost-
effectiveness of a school-based behavioural
change intervention aimed at children to negoti-
ate and implement smoking restrictions in
homes.
▪ A pilot that is rooted in a well-developed smoke-
free intervention (SFI) that has shown promising
results from the feasibility study in Dhaka,
Bangladesh.
▪ The first study of secondhand smoke (SHS)
exposure in children that will assess a variety of
clinical, behavioural and school
performance-related outcomes (in children),
such as the frequency and severity of respiratory
illnesses, healthcare contacts, school absentee-
ism, smoking uptake and improvements in their
lung function, quality of life and academic
performance.
▪ The only limitation is that the trial is not powered
to show the effectiveness of the SFI, which can
be attributed to its design being a pilot trial to
inform plans of a bigger definitive cluster RCT in
the future.
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reduced exposure to SHS and its associated morbidity
and mortality.12 However, for most non-smoking women
and children, homes and cars remain important sources
of SHS exposure. Additional measures are therefore
required to protect non-smokers, particularly children,
from SHS exposure. In Bangladesh, exposure to SHS
has been recognised as a particularly serious threat to
children’s health given the high prevalence of smoking
by male adults.13 However, smoking bans in public and
workplaces are only partially implemented and little has
been done to protect children from exposure to SHS at
home. We carried out a recent household survey that
revealed that most households (56%) have at least one
smoker and that smoking indoors in front of children
(40%) was a common practice.14
The evidence for the effectiveness of interventions to
provide children a smoke-free environment at home is
scarce. A recent Cochrane review concluded that, despite
several studies on parental education and counselling
programmes, their effectiveness in reducing children’s
tobacco smoke exposure has not been clearly demon-
strated.15 An alternative approach, for which there is also
only very limited research, is to encourage children them-
selves to negotiate smoking restrictions in their house-
holds.16 We developed a school-based SFI and found
through a feasibility trial in Dhaka, Bangladesh (24
schools, 781 children) that it was acceptable and success-
ful in getting children to negotiate implementation of
smoking restrictions at home (OR 3.9; 95% CI 2.0 to
7.5).17 Schools were also willing to participate and be ran-
domised in a trial. Encouraged by these ﬁndings, we now
wish to assess if the success of this intervention also trans-
lates to reduce SHS exposure in children and improves
their health outcomes and academic achievements.
The principal question for our planned follow-on
deﬁnitive trial is: What is the effectiveness and cost-
effectiveness of a school-based SFI in reducing children’s
exposure to SHS (primary outcome), the frequency and
severity of respiratory illnesses, healthcare contacts,
school absenteeism, smoking uptake and in improving
their lung function, quality of life and school
performance?
Prior to conducting a deﬁnitive trial to answer the
above question, we wish to ﬁrst conduct a pilot trial that
informs the parameters required for conducting the
deﬁnitive trial.18 Our speciﬁc research questions for this
pilot study are therefore to ascertain:
▸ What are the recruitment and attrition rates for
schools (clusters) and children?
▸ What is the feasibility and acceptability of measuring
the primary and secondary outcomes?
▸ What is the likely effect size and its variance in rela-
tion to the primary outcome measure?
▸ What is the intracluster correlation coefﬁcient (ICC)
among children for the trial outcomes?
▸ What is the ﬁdelity of delivering SFI in schools?
▸ What are the costs associated with delivering SFI
through schools?
▸ What would facilitate and hinder in scaling up SFI in
schools and their curriculum?
▸ What is the frequency and nature of any adverse
events (AE)?
METHODS AND ANALYSIS
This is a two-arm pilot cluster randomised controlled trial
(RCT) of SFI with an embedded preliminary health eco-
nomic analysis and a qualitative evaluation. This is a
2-year study. We will recruit participants (schools and chil-
dren) and start baseline assessments in the ﬁrst
3 months. Between months 3 and 6, we will complete all
baseline assessments, randomise schools and start deliver-
ing the intervention. We expect respective schools to
have delivered the intervention by month 9, which means
that all follow-ups will be completed between months 18
and 21. We will complete the analysis in the last 3 months
and submit our ﬁnal report at the end of 2 years.
Study sites
The study will be conducted in Mirpur and Savar areas of
Dhaka Division, Bangladesh. According to the 2011
census, these two sites geographically typify urban and
peri-urban contexts, respectively, with a population of
more than a million in each area. Mirpur is a typical
densely populated urban area in Dhaka with the majority
of its population dependent on non-agricultural livelihood
and with access to amenities such as paved road, electricity,
gas, water supply and drainage systems. On the other
hand, Savar is a peri-urban area located 24 km northwest
of Dhaka. The majority of its population is dependent on
agriculture and industry located around Dhaka. These two
areas have been chosen for their typical demographic and
socioeconomic structures and existing links with the local
communities, schools and health facilities.
Study clusters (schools)
We will recruit 12 schools from the above two sites, six
from each area. The key eligibility criteria are as below.
Inclusion criteria (schools)
We will include both public and private schools if they:
▸ Follow mainstream curricula approved by the educa-
tional authorities.
▸ Have year-5 classes, with >40 and <120 year-5 children
(10–12 years old) per class.
▸ Have a ‘no-smoking’ policy and all participating
year-5 teachers are self-reported non-smokers. It
would be desirable to exclude those schools that have
any year-5 teachers who smoke. However, given the
difﬁculty in verifying smoking status, we will not make
this a mandatory exclusion criterion.
Exclusion criteria (schools)
We will exclude schools if they:
▸ Have only primary school classes—these will be
excluded due to the challenges of following up chil-
dren as they move to a secondary school in year 6.
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▸ Teach in English medium rather than in Bangla—
such schools are in a minority in Bangladesh and
usually cater for children from afﬂuent backgrounds.
There will be very few such schools in our proposed
study sites.
▸ Have already received training on SFI in a previous
project, unless the teachers who were trained have
left the school.
▸ Are religious or faith-based schools not following the
prescribed curricula.
Identifying and recruiting eligible clusters (schools)
We will survey the study sites and prepare a list of
schools containing information on their class sizes in
year 5, primary or secondary school status, public or
private status, co-education or single sex schools and
their medium (language) of teaching. Schools will be
assessed for eligibility, using the criteria stated above.
Once found eligible, these will be approached for
recruitment. We acknowledge that some of the eligibility
criteria can only be assessed after approaching schools
and talking to the headmaster and year-5 teachers.
Those schools identiﬁed and found eligible on the basis
of the available information will be sent a letter addressed
to the head teacher, including brief information about the
trial and inviting the school to take part in the trial. We
will offer to meet head teachers face to face to provide
verbal information and responses to their queries. We will
also explain random allocation. Interested schools will be
provided with a detailed information sheet.
Those who are not eligible or who meet the eligibility
criteria but do not agree to participate after receiving
the trial information will not be enrolled in the trial.
However, their reasons for not meeting the eligibility cri-
teria or declining to participate will be recorded.
Once recruited, we will endeavour to keep all schools
on board and included in the study. If, for any reason, a
school withdraws before randomisation, we will recruit a
new school to replace the withdrawing school. However,
if the withdrawal takes place after randomisation, we will
not replace such a school and will include it in our
analyses.
Study participants (children)
We will recruit 360 year-5 (ie, at least 30 from each
school) schoolchildren (10–12-years) after seeking their
parents’ consent and their assent through schools.
Being the oldest year in primary school years, we con-
sider this year to be the optimal age group to under-
stand the message and engage with their family
members to implement smoking restrictions. The key eli-
gibility criteria are as below.
Inclusion criteria (children)
We will include children if they are:
▸ Studying in year-5 in the participating school and
their age range is between 10 and 12 years;
▸ Self-reported non-smokers.
Exclusion criteria (children)
We will exclude children if they have any of the follow-
ing conditions/situations that the school is aware of:
▸ Physical or mental disabilities;
▸ Learning difﬁculties and/or special learning needs;
▸ Behavioural problems and/or conduct disorder;
▸ Serious medical condition which is either life-
threatening or requires regular hospitalisation.
Identifying, recruiting and consenting eligible participants
(children)
We will request schools to prepare a list of eligible chil-
dren including all those who meet the inclusion criteria
and excluding all those who fall into the exclusion cri-
teria list. Once an eligibility list is prepared, we will give
all schools the required number of trial information
packs to proceed with the recruitment.
All children participating in this trial will be under
16 years and therefore parental/carer consent is
required for them to take part. On the basis of our
experience of conducting a previous study in schools in
Bangladesh (approved by a national ethics committee)
and advice received from a number of academics who
work in schools in the UK, we will obtain parental
consent on an opt-out basis as follows. The participating
schools will send out the trial information packs to
parents of all eligible children, containing an informa-
tion sheet, and a parent/carer opt-out consent form. We
will ask parents/carers to discuss the trial with their
child/children. If either the parents or children are
unwilling or unable to participate in the trial, we will ask
the parents to indicate this by either sending us an
opt-out consent form in a self-addressed prepaid enve-
lope or calling/texting/emailing us on the contact
details provided within the information pack. We will
give parents/carers a minimum period of 7 days to indi-
cate if they do not wish their child(ren) to take part in
the study.
Moreover, at the time of recruitment, children will be
of an age (10–12 years) where they are able to under-
stand their potential involvement in research and can
make an informed decision. Children will therefore be
provided with an age appropriate information sheet,
which will be given out to them at school. If children
are unwilling, they can either let their teachers or
parents know, as they feel appropriate. If parents indi-
cate their disapproval for their child to take part in the
study, this will supersede the child’s assent to participate.
Any child who has, or whose parents/carers have,
declined to participate will be taken out from the list of
eligible children by the school, and the ﬁnal list will be
handed over to the research team. All participating chil-
dren will be given an enrolment number (including a
code for school), which will be recorded on the ﬁnal list
of eligible children, printed on all enquiry tools and
entered in the database.
Those children who do not meet the eligibility cri-
teria, or those who meet the criteria but either their
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parents or they would not agree to participate after
receiving the trial information, will not be enrolled in
the trial. However, their reasons for not meeting the eli-
gibility criteria or declining to participate will be
recorded. This information will be kept completely
anonymous.
A child can be withdrawn from participation at any
time after enrolment or allocation. If a child is with-
drawn from the intervention for any reason, their
follow-up assessments and data collection will continue
as per protocol unless the parents/carers or child specif-
ically asks for their withdrawal from the study com-
pletely. However, if the child is withdrawn completely
from the study, then no more data will be collected.
They will still be included in the analysis and counted as
lost to follow-up. The information already collected will
be kept in the database unless the parents/carers or
child speciﬁcally asks for their information to be
removed.
Cluster (schools) randomisation and allocation
Once the necessary baseline data have been logged into
a database, the participating schools will be randomly
allocated to each of the two arms, intervention and
control, on an equal basis (ie, six schools in each arm).
Each intervention school will be paired with a control
school for follow-up purposes. We will use a restricted
method of allocation called minimisation, which achieves
balanced groups efﬁciently. For this, we will use three cri-
teria, public/private status of school, boys to girls’ ratio,
and mean number of children exposed to SHS at
baseline.
Intervention details
Once children are enrolled, schools will be randomised
to receive either the SFI or treatment as usual. These
treatment conditions are described as below.
Smoke free intervention
SFI is based on behaviour change techniques identiﬁed
in the literature,19 and has been developed by a tech-
nical working group including schoolteachers, represen-
tatives of civil society organisations, public health
practitioners, educational experts and behavioural scien-
tists from Bangladesh and the UK. Once agreement was
reached on the key messages, a range of educational
materials, both in Bangla and English, were developed
addressing different learning styles. The training materi-
als for schoolteachers have been pre-piloted and revised
according to the suggestions made by a user group and
the technical working group. A manual has also been
prepared to help schoolteachers in delivering SFI. It is
envisaged that at least two year-5 teachers (one class
teacher and one support teacher) will be trained in
each school.
All participating children in the intervention arm will
receive the SFI delivered by their teachers. Teachers will
receive prior training in delivering the intervention. The
intervention will consist of:
▸ Two 45 min sessions delivered over 2 days by school-
teachers. The duration of these sessions is consistent
with regular school lessons. Each session consists of a
range of educational activities including classroom
presentations, quiz, interactive games, storytelling and
role-play—vicarious learning techniques are utilised
in many of these activities. The presentation, quiz
and games are designed to increase pupils’ knowl-
edge about SHS and related harms, and motivate
them to follow three easy steps to make their homes
smoke-free. The storybook and role-play focuses on
enhancing children’s negotiation skills, building their
conﬁdence within the Bangladeshi cultural context.
While the storybook depicts the challenges of negoti-
ating with elders, the role-play has hypothetical scen-
arios where children had an opportunity to practise
and demonstrate how and when they can discuss and
negotiate with elders to persuade them not to smoke
inside homes.
▸ A set of four refresher sessions (15 min each) to
reinforce key messages delivered in the initial ses-
sions, to be delivered once a week over 6–7 weeks
after the two initial sessions. During each session, the
teacher reminds children of the key points of the
main session by asking questions (5–7 min), and then
encouraging students to share their experiences of
whether they could initiate discussion at home, what
challenges they faced, what is their plan to do next
and what would be the best way to convince the
elders (8–10 min). The length of these sessions is
consistent with the duration of the school assembly.
▸ Children are given a promise form that contains pic-
torial and written messages on the hazards of SHS, a
pictorial step-guide for families on how to make their
homes smoke-free and a tear-off slip to make a com-
mitment to impose smoking restrictions at home.
Children take promise forms to their parents, show
them the messages and negotiate with them to
‘sign-up’ to the SFI ‘promise’ form. One of the impli-
cations is that even if parents are non-smokers, they
will not allow other smokers (residents and visitors)
to smoke inside homes. In addition to delivering the
intervention, teachers will also be trained to support
children in this process.
Treatment as usual
Schools in the control arm will receive the intervention
at the completion of the trial.
Outcomes assessment
Speciﬁc outcomes for this pilot trial include: (1)
number of clusters (schools) and the size of each cluster
(children) for the main trial; (2) recruitment and attri-
tion rates for clusters and participants; (3) length of
time required to reach participant recruitment satur-
ation for each cluster; (4) descriptive data on
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characteristics of participating clusters and participants;
(5) reasons for ineligibility of clusters and participants;
(6) reasons for non-participation/non-consent of clus-
ters and participants; (7) estimate of the effect size of
the primary outcome in a deﬁnitive trial (salivary coti-
nine); (8) calculation of the ICC for the trial outcomes
in order to inform the sample size required for the
main trial; (9) estimate of contamination between clus-
ters; (10) the costs associated with delivering SFI; (11)
ﬁdelity of the intervention and (12) the time and
resources required in measuring all outcomes, including
the response rate to obtaining saliva samples and the
extent and type of missing data with reasons. We will
assess and report on these outcomes as part of our data
collection and analysis plan.
The outcomes for the deﬁnitive trial will also be mea-
sured before and after the intervention in each of the
study’s arms. We ﬁrst describe these outcomes and then
the process and schedule of assessing these (table 1).
Primary outcome
We will assess children’s exposure to SHS by measuring
their salivary cotinine levels. Salivary cotinine concentra-
tion, a sensitive biochemical marker, is strongly asso-
ciated with the exposure to SHS at home. It has a
half-life of 20 h. It is a widely recognised method for
detecting both active and passive smoking and has been
used in several surveys and studies. It involves keeping a
sterile swab in the mouth for a few seconds, allowing it
to absorb saliva and then transferring it to a sterile
plastic container. The samples are subsequently analysed
and a gas-liquid chromatography technique can detect
cotinine levels as low as 0.1 ng/mL.
Once children are enrolled in the study, saliva samples
will be obtained from all participating children at base-
line and also at 2-month post-intervention. Samples can
be stored for a period of 2 weeks before being trans-
ported to a specialist laboratory (ABS Labs) in the UK
for these to be analysed using a gas-liquid chromatog-
raphy technique. Samples will be sent in two batches at
baseline and two at the ﬁrst follow-up. Samples will not
contain any participant identiﬁable information and will
only have the trial enrolment number. Their reports will
be sent back to the central research ofﬁce in Dhaka
where these will be entered in the database.
Secondary outcomes
These will include the below.
Frequency and severity of respiratory symptoms
Participating children will keep diaries and record
respiratory symptoms on a nominal severity scale from 0
to 3 as used by Chauhan et al.20 For each item, ‘0’ repre-
senting the absence of a symptom, 1 representing mild,
2 representing moderate and 3 representing the greatest
severity level. The upper respiratory tract symptoms will
include having a runny nose or sneezing, blocked or
stuffy nose, sore throat or hoarse voice, headaches or
face aches, aches or pains elsewhere, and feeling chill,
fever or shivers. The lower respiratory symptoms will
include cough on waking, wheeze on waking, cough
during the day, wheeze during the day, shortness of
breath during the day, night cough and wheeze or short-
ness of breath during the night. Scores will be recorded
daily and added up to give daily upper and lower
respiratory-tract scores, respectively.
Three hundred and sixty diaries to record respiratory
symptoms will be printed and given to all participating
children. These diaries will have three sections. Section
1 will record symptoms from the day intervention is
delivered until the end of month 2; section 2 from the
start of month 3 until the end of month 6; and section 3
from the start of month 7 until the end of month 12. At
each follow-up, one section will be taken out of the diary
by the researchers and data will be entered in the data-
base. All children will provide data on section 1. Only
those children whose cotinine levels are indicative of
passive smoking at baseline will provide data on sections
2 and 3. Children will be told whether to stop or keep
collecting information in their diaries in a letter.
Lung functions
We will measure lung functions on all participating chil-
dren at baseline and on children with positive salivary
cotinine at months 2, 6 and 12. For this, we will use a
spirometer as per British Thoracic Society guidelines.21
This will involve measuring forced vital capacity, forced
expiratory volume in the ﬁrst second (FEV1) and peak
expiratory ﬂow using a handheld Micro1 spirometer. We
will ﬁrst record the height of all participating children at
baseline. We will enter details of the patient’s sex, ethnic
group, age and height into the spirometer. We will then
ask each child to blow into a disposable mouthpiece
attached to the spirometer at least three times as per
guidelines. The best of the three readings will be taken.
The spirometer will also calculate the percentage of the
predicted normal values (using Asian reference values)
as they have the reference data already programmed
into them. The spirometer will print out a lung function
test report for each participant, which will be attached
to the participant baseline and follow-up questionnaire,
respectively. Spirometers will be cleaned according to
the manufacturer’s guidelines and their accuracy
checked regularly.
Smoking-related behaviours
We will ask the children to self-report levels of smoking
restrictions and social visibility of smoking at home
through a questionnaire. We will assess smoking restric-
tions using the following questions: (1) ‘Where do
people smoke in your house who live with you?
(Anywhere inside the house, in some rooms, only in one
room, or only outside the house)’; (2) ‘Where do
smokers who visit your house smoke? (Anywhere inside
the house, in some rooms, only in one room, or only
outside the house)’. We deﬁne ‘open space outside
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house’ as those spaces, which are still within the house
premises but not covered by a ceiling, such as the
veranda, balcony, yard, garden, lawn, patio and open
roof. Social visibility will be assessed by the following
questions; (1) ‘Do people who live with you smoke in
front of children?’ (2) ‘Are people who visit your house
allowed to smoke in front of children?’ For each
outcome, the response categories across the two ques-
tions will be combined to form a composite variable
(index) for analysis purposes.
Using the same questionnaire, we will also assess
children’s self-reported attitude towards smoking and
intention to start smoking. We will use a ﬁve-point
smoking uptake scale22 to categorise children as non-
susceptible non-smokers, susceptible non-smokers, early
experimenters, advanced experimenters and established
smokers.
The above assessments will be carried out both at
baseline and at all follow-up time points.
Health service use
We will use a health service utilisation questionnaire pre-
viously used in the Muslim communities learning about
secondhand smoke (MCLASS) trial,23 to collect the
number and type of contacts with doctors/nurses, hos-
pital admissions, pharmacy visits and antibiotic prescrip-
tions. This information will be part of the baseline
questionnaire but will also be assessed at all follow-up
time points.
Quality of life
Quality of life (generic) will be assessed using a short
quality of life questionnaire for children EQ-5DY.24 The
questions will be included in the baseline and follow-up
questionnaires.
Other confounding variables
At baseline, we will also ask children to report on some
of the basic sociodemographic details on the question-
naire. These will include age, gender, household amen-
ities, family structure, cohabiting smokers—including
parents, pet ownership, overcrowding—number of
rooms and residents, built environment, neighbour-
hood, presence of mould/moisture in the child’s home,
and use of gas for cooking or gas/kerosene/oil heater.
Furthermore, we will include information on children’s
medical history (particularly asthma and chest infec-
tions) and use of any regular medications.
Absenteeism and academic performance
Each participating school will be asked to provide a
report on the academic performance of participating
children using the Academic Performance
Questionnaire (APQ).25 This is a 10-item questionnaire
to be completed by teachers. Using four-point and ﬁve-
point ordinal scales, it measures a child’s performance
in reading, mathematics, writing and homework. This
questionnaire will be completed at baseline and at all
follow-ups. In addition, schools will also be requested to
Table 1 Table and schedule of assessments within CLASS II trial
Study period
Enrolment Allocation Postallocation Close-out
Time points Baseline—t0 0 Month 1—t1 Month 2—t2 Month 6—t3 Month 12—t4 Month 15—tx
Enrolment
Eligibility screen X
Parental consent X
Children’s consent X
Allocation X
Interventions
Smoke-free intervention fx1
Controls fx2
Assessments
Sociodemographic and medical history
Personal details X
Household details X
Medical history X
Smoking-related behaviours
Smoking restrictions X X X X
Attitudes towards smoking X X X X
Health service use X X X X
Quality of life X X X X
Exposure to SHS—salivary cotinine X X
Lung health X X
Respiratory symptoms diary X X X X
Lung functions—spirometry X X X X
Academic assessment
Academic performance questionnaire X X X X
School absenteeism report X X X X
CLASS, Children Learning About Secondhand Smoke; SHS, secondhand smoke.
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provide a record of child’s absenteeism from school
including the number of days missed every month in
between two assessments.
Fidelity index
The research team will use a ﬁdelity index, mapped
onto the behaviour change techniques that underpin
SFI, to assess intervention adherence. This will be in the
form of a checklist, which will be used to monitor
the delivery of SFI sessions. One of the members of the
research team will attend all SFI sessions and using the
above checklist will score ﬁdelity to SFI.
Data collection
Prior to randomisation, a baseline assessment will
include a classroom-administered questionnaire (includ-
ing EQ-5DY, health service use and smoking behaviour)
to be completed by participating children, APQ and
school absenteeism form to be completed by school tea-
chers, lung function assessment and saliva sample collec-
tion by the research team for each child (table 1). Each
child will also receive a respiratory symptoms diary with
instructions on how to use it. Follow-up assessment will
take place at 2, 6 and 12 months post-allocation involv-
ing only those children whose cotinine levels were indi-
cative of SHS exposure at baseline. All assessments
carried out at baseline will be repeated at the follow-up
assessment except cotinine levels which will only be
assessed at month 2.
Qualitative evaluation
Teachers and head teachers (2 and 1 per school; 12 and
6 in total, respectively) from the six intervention schools
will be interviewed once the SFI has been delivered.
Semistructured interviews will explore the barriers and
facilitators to delivering the different components of the
SFI, including training and resource needs. Interviews
will be conducted using a topic guide to ensure consist-
ency, with ﬂexibility to allow participants to generate nat-
uralistic data on what they see as important. Where
possible, the interviews will be conducted face to face at
school. If this is not possible, then telephone interviews
will be done. With the participants’ permission, inter-
views will be audio recorded digitally and transcribed
verbatim with anonymisation of all personal data.
Data management and archiving
Data will be initially collected in the form of a paper-
based questionnaire. Containing no participants’ identi-
ﬁable information, these will be collected by the
research team and kept in a locked cupboard separate
from the consent forms. Once a week, data will be
entered in the trial database, which will be kept at a
secure server. The paper copies will continue to be kept
in a securely locked cupboard.
In line with the Data Protection Act and the Research
Governance Framework for Health and Social Care
Research, at the end of the trial, data will be securely
archived by the University of York for a minimum of
5 years. Following authorisation from the sponsor,
arrangements for conﬁdential destruction will then be
made. If an individual withdraws consent for their data
to be used, it will be conﬁdentially destroyed.
AEs procedures
We are expecting a minimal number of adverse and no
serious AEs (SAEs) during the study. SFI is an educa-
tional intervention and has been very well received in
our previous studies17 without leading to any directly
related AEs. Nevertheless, there will be a vigilant surveil-
lance system in place for AEs occurring during the
course of the trial with particular emphasis on identify-
ing, recording, reporting and managing any SAEs. We
will sensitise schoolteachers to look for signs of any AEs
resulting from the interactions between children and
their parents. We will also encourage children and
parents to report any related adversities.
Definitions
Adverse event
An AE is any untoward clinical event in a trial partici-
pant, which may or may not be related to the study inter-
vention. The clinical event could be an unfavourable
and unintended symptom, sign, medical condition,
abnormality or disability that has appeared or worsened
during the course of the trial, regardless of a causal rela-
tionship to the study intervention.
Serious adverse event
A SAE is any clinical occurrence that:
▸ Results in death of the participant;
▸ Is life-threatening, deﬁned as an event in which the
participant is at risk of death during the event. This
does not refer to incidents that hypothetically might
have led to death if the event worsened;
▸ Results in hospitalisation or prolongation of hospital
stay;
▸ Results in persistent and/or signiﬁcant disability and/
or incapacity;
▸ Birth defect or congenital anomaly;
▸ Any medical condition that may not be life-
threatening, disabling or resulting in hospitalisation
but requiring medical or surgical intervention to
prevent any of the above outcomes.
Please note that any planned surgery or medical pro-
cedure will not be considered as an SAE.
Detecting, recording and reporting of AEs and SAEs
In the event of any AE reported by the child, their
parents/carers or schoolteachers, the research assistant
will complete an AE form, which will include medical
diagnosis, if relevant and available. The research assist-
ant will also call the trial manager on the same day pro-
viding a verbal report of the event. The trial manager
will ensure that the event is classiﬁed appropriately after
receiving the verbal report. All AEs will be reported to
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the principal investigator, Bangladesh (RH) within
3 days of detection. AE data will be collated and
reported to the trial sponsors and National Bioethics
Committee at six monthly intervals. These must also be
reported to the Study Operational Committee (SOC)
and the Independent Trial Steering Committee (ITSC)
at their regular meeting. All AEs that have the potential
to develop into SAEs will be followed to resolution or
stabilisation and reported as SAEs if they become
serious. All SAEs must be reported to the principal inves-
tigator within 24 h of detection and should also be
reported to the trial sponsors and National Bioethics
Committee within three working days. All serious events
must also be reported to all study investigators and the
chair of the ITSC within 3 days. The chief investigator
will have the overall responsibility to ensure that all AEs
are reported according to the above protocol.
Evaluation of AEs and SAEs
In addition to assessing seriousness, the trial manager
will assess all AEs for causality, severity and expectedness.
Assessment of causality and relatedness
This will be done in consultation with the principal
investigator and the event will be classiﬁed as follows.
Unrelated: When the event is considered not related to
the study intervention.
Possibly: When an association of the event with the
study treatment cannot be ruled out.
Probably: When temporal association and an absence
of any other explanation suggest that the event could be
related to the study intervention.
Deﬁnitely: Evidence suggests that the study intervention
is the most likely cause of the event.
Assessment of severity: The trial manager will make the
following assessment based on severity, which should not
be confused with seriousness (a statutory deﬁnition) dif-
ferentiating between AEs and SAEs.
Mild: Those events that cause minimal discomfort, are
easily tolerated and do not interfere with routine life
activities.
Moderate: Those events that cause moderate discomfort
and do interfere with routine life activities.
Severe: Those events that cause much discomfort and
lead participants to stop their routine life activities.
Assessment of expectedness
If the event is judged to be an adverse reaction, serious
or otherwise, it must be judged on expectedness based
on what is already known about the intervention under
study.
Follow-up procedures
These events will be followed up until resolution or
returning to a stable medical state. We will not expect
any events to be relevant to the trial that occur after the
completion of follow-up, and therefore no active surveil-
lance will continue beyond trial completion.
Nevertheless, any event reported to the trial manager
will be recorded and kept in the records along with
other trial data.
Statistical considerations
Sample size
This pilot trial will inform sample size considerations for a
deﬁnitive trial. Therefore, no formal sample size calcula-
tions have been undertaken. However, with the number of
clusters (and cluster size) we seek to enrol, we should be
able to estimate recruitment and attrition rates, effect size
and ICC. For our primary outcome, the pilot trial will
provide us with a more accurate effect size and SD values.
If the effect of intervention is similar to that observed in
our feasibility study and implementing smoking restrictions
at home imply a reduction in SHS exposure, we should
expect 40–50% reduction in children’s exposure to SHS.
The ICC observed in our feasibility trial was 0.18, but it was
estimated for a proximal outcome. Therefore, in this study,
we will be able to determine a more accurate estimate of
ICC based on a distal outcome. Assuming that at least 360
children (and their parents/carers) agree to participate
from each school, we expect at least 120 children with a
positive cotinine test as baseline. On the basis of the feasi-
bility trial, we expect no schools to drop out from the trial
and the children’s attrition rate to be <20%. According to
this, we estimate that we will be able to retain at least 96
children by the end of the trial. However, actual attrition
rates will be found to make adjustment to the sample size.
Statistical analysis
We will conduct a preliminary analysis summarising: par-
ticipant (individual and cluster) characteristics; attrition
rates; likely estimates of effect and ICC for the out-
comes. This will also include a comparison between par-
ticipants with detectable and zero levels of cotinine at
baseline. Although determining differences in the out-
comes between the two arms is not the purpose of this
study, we will summarise outcomes at both cluster and
individual levels using an intention-to-treat principle and
estimate 95% CIs for any differences. All analyses will be
conducted using SAS 9.4 (Institute Inc, Cary, North
Carolina, USA).
Qualitative evaluation
Interview data will be analysed using thematic analysis,26
which is a method of ‘identifying, analysing and reporting
patterns (themes) within the data’. This is a useful
approach for producing qualitative analyses suited to
informing programme evaluation and development. The
focus of the analysis will be to identify key issues in deliver-
ing the SFI that may inform the process of ‘scaling up’ the
intervention for the deﬁnitive trial. Six phases of thematic
analysis will be followed: familiarisation, generating initial
codes, searching for themes (prior—informed by study
objectives as well as emergent), reviewing themes, deﬁning
and naming themes, writing the ﬁnal report. Negative
cases will be actively sought throughout the analysis and
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emerging ideas and themes modiﬁed in response.27 NVivo
will be used to manage the data.
Health economics
In the pilot phase of this trial, we will assess the feasibility
and acceptability of undertaking a full cost-effectiveness
analysis. The ﬁrst stage will estimate the cost of delivering
the intervention. Intervention costs will include the time
and resources needed to deliver the SFI intervention. We
will also pilot a service use questionnaire to record utilisa-
tion of healthcare resources. These include doctor and
hospital visits for the treatment of childhood conditions
related to the inhalation of passive smoke and also medi-
cations dispensed for such illnesses. We will audit and
analyse the returned data for completeness and revise
questionnaires where appropriate to improve data
capture in a full trial.
The purpose of the pilot phase is to inform a cost-
effectiveness analysis in a full trial with regard to inter-
vention cost and data collection. In a full trial, we will
conduct an incremental cost-effectiveness analysis of the
smoke-free homes intervention over and above the
control. Total costs include the costs of the intervention
(SFI) as outlined above and wider healthcare costs such
as doctor and hospital visits for childhood illness related
to the inhalation of passive smoke (asthma, wheezing,
middle ear infections, respiratory tract infections and
meningitis). We will also record and calculate the costs
of medications related to these illnesses, which are dis-
pensed. In the full trial analysis, the quantities of
resource use (contacts) are multiplied by local unit costs
to derive an individual cost proﬁle.
The main outcome for the health economic analysis of
the full trial will be changes in quality adjusted life years
(QALYs), which will be computed from the EQ-5DY ques-
tionnaire24 completed by trial participants. In a full trial,
we propose a within-trial cost-effectiveness analysis com-
bining the costs of the intervention and wider treatment
with QALY gains to derive an incremental cost per QALY.
The cost per QALY will inform the value for money
afforded by investment in the SFI intervention. We will
perform sensitivity analysis to investigate the robustness
of the results. We will also explore potential differences in
cost-effectiveness between centres within the trial using
multilevel modelling techniques.
Study organisational structures
The study will be managed and steered by a SOC and an
ITSC. The SOC will consist of all study investigators and
will be responsible for the delivery of the project. It will
meet on a bimonthly basis over Skype/teleconference
and will review trial progress, respond to any concerns
raised by the trial manager and the principal investiga-
tor, propose remedial actions and detect any forthcom-
ing problems. The ITSC will be set up and will include
an independent chair, at least two other independent
members, a chief investigator, a research fellow, a trial
manager, a trial statistician and the principal investigator.
It is likely to meet every 6 months but will decide on the
frequency of meetings. The ITSC will oversee the trial
and ensure that the trial is conducted according to the
protocol and within the underlying ethical framework.
Members will also provide advice outside these meetings
according to their area of expertise at key stages via
email, phone or, if needed, face to face.
Data monitoring
Data will be monitored for quality and completeness
ﬁrst by the trial manager and then by the principal
investigator (Bangladesh) using veriﬁcation, validation
and checking processes. Once data are entered into the
database, all entries for the primary outcomes and a
random sample of 10% entries for other variables will
be double checked by the trial manager. In addition, all
paper-based forms will be double-checked and validated
against the original forms.
Protocol amendment
All amendments to the protocol will be ﬁrst discussed
with the chief investigator and then submitted to the
Bioethics Committee for formal approval. A judgement
will be made on the nature of amendment, that is,
major or minor, as per guidance from the Bioethics
Committee. All minor amendments will be implemented
once notiﬁed to the Bioethics Committee and all major
amendments will be implemented once approved by the
Bioethics Committee.
Protocol violations and deviations
The research team will not deviate from the protocol
without agreement with the chief investigator and securing
an agreement with the Bioethics Committee and SOC
except in situations where a deviation is necessary to
remove an immediate hazard to the participants. Any such
deviations (both nature and reason) should be recorded
in the AE form and, if necessary, an amendment to the
protocol must be secured through a formal process.
Quality assurance
The study will be conducted in accordance with current
MRC Good Clinical Practice guidelines and the NHS
Research Governance Framework.28 Administrative
approval will be sought from each participating school.
The study will be subjected to all research management
and governance procedures in place at the University of
York including the requirement for audit.
ETHICS AND DISSEMINATION
The trial will be conducted to protect the human rights
and dignity of the participant as reﬂected in the 1996
version of the Helsinki Declaration. Participants will not
receive any ﬁnancial inducement to participate in the
trial. In order to protect the trial participants, the follow-
ing provisions will be made/upheld; the trial has been
designed to minimise the burden of participants and
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any foreseeable risk in relation to the intervention
involved; the explicit wishes of the participant will be
respected including the right to withdraw from the trial
at any time; the interest of the participant will prevail
over those of science and society; provision will be made
for indemnity by the investigator and sponsor.
We have received ethical approval from the University
of York and the Bioethics Committee of Bangladesh
Medical Research Council.
Some of the ethical issues considered are as follows:
(1) children’s participation raises issues around compe-
tence, vulnerability and powerlessness. In this study, chil-
dren’s wishes and their welfare will take precedence over
research requirements. Research burden will be kept to
a minimum. (2) Children and their families will not be
reimbursed ﬁnancially; however, small incentives in the
form of school stationery will be offered. (3) On
the basis of our feasibility work, it is highly unlikely that
the children will face any adverse reaction from their
families. Obtaining saliva sample for cotinine is also not
harmful to children, neither it could disclose presence
of any medical condition. (4) All participants’ data will
be kept conﬁdential and in password-protected servers.
Confidentiality
All information collected during the course of the study
will be kept strictly conﬁdential. Information will be
held securely on paper and electronically at the central
research ofﬁce. The researchers will also comply with all
aspects of the 1998 Data Protection Act and operation-
ally this will include:
▸ Consent from participants to record personal details
including name, date of birth and address.
▸ Appropriate storage, restricted access and disposal
arrangements for participant’s personal details.
▸ Identiﬁable information will be collected on the
consent form when he or she is consented into the
trial, but all other data transferred to or from
the central research ofﬁce will be coded with a trial
enrolment number and will not include participants’
identiﬁers.
If a participant withdraws consent from further trial
participation (please note that this would be different
from withdrawing from the study intervention), no
further assessments will be conducted but their data
already collected will remain on ﬁle and be included in
the ﬁnal study analysis (unless the participant has specif-
ically requested for their data to be destroyed).
Dissemination plans
This is a proposal for a pilot cluster RCT of SFI school-
based intervention, and therefore its ﬁndings will
inform a future deﬁnitive trial rather than the effective-
ness and cost-effectiveness of the intervention.
Nevertheless, the potential impact of this study and the
subsequent research is likely to be high as it addresses a
key priority in children’s health, uses an innovative
behavioural approach, employs a robust study design,
engages with primary schools and attempts to measure a
variety of health and educational outcomes. Our pro-
posed pilot and the subsequent deﬁnitive trial could
lead to:
▸ A wider use of SFI or similar approaches to address
SHS exposure. If shown to be successful, this could
lead to improving children’s physical health and aca-
demic performance. It will also contribute towards
shifting social norms of smoking in the house and in
front of children, which could encourage smokers to
consider quitting. If it helps in changing children’s
own attitudes towards smoking, SFI could become a
successful preventative measure.
▸ If shown to be successful, the behavioural approaches
and settings used in our study could also be used to
tackle other unhealthy behaviours such as poor diet
and physical inactivity. Children’s health behaviours
are often determined by parenteral and sibling’s atti-
tudes and behaviours. Our proposed approach lends
itself nicely to address other health behaviours and
can result in improving family health in ways that go
beyond what is proposed here.
▸ Our proposed methods and measures can help
researchers from a range of disciplines. Such
methods and measures are rarely used in low-income
settings causing a dearth of experience and related
data. Our study will provide both experience and
useful data in a setting and population group where
both are scanty. Other researchers would beneﬁt
from this and can use parameters generated from
this research to design and conduct their own studies.
The following is a list of academic and non-academic
audience for this study with a set of activities that will be
undertaken to engage with them to maximise its impact.
Academic audience
▸ Public health researchers interested in generating evi-
dence for school-based interventions aimed at
improving children’s health.
▸ Behavioural scientists interested in building an evi-
dence base for behaviour change techniques.
▸ Trialists with an interest in school-based trials in low-
income settings.
▸ Clinicians who would wish to use lung health mea-
sures in studies where the end points are similar to
ours.
▸ Education researchers who are interested in studying
the relationship between health, school absenteeism
and academic performance using standardised
instruments.
▸ Health service researchers interested in children’s
health and their use of health service.
▸ Researchers in tobacco control interested in measur-
ing SHS exposure in children.
▸ Health economists who wish to carry out economic
evaluation of school-based interventions.
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▸ Students of health, medicine and social care will
beneﬁt as learning from this research will be incorpo-
rated within the relevant curriculum.
Ways of engagement
▸ We will publish the results of the trial in a high-
impact peer-reviewed journal
▸ We will also publish the results of the qualitative com-
ponent of the research in a journal specialising in
smoking issues (eg, Tobacco Control) or general public
health issues (eg, BMC Public Health)
▸ We will publish our pilot trial protocol in an open
access journal. In addition, we will also present our
ﬁndings in an international public health conference
and an international tobacco control conference
▸ We will also publish an abstract of our ﬁndings on
our website
▸ We will also present our work to regional research
meetings
▸ We will also work with our network of other research-
ers (World Universities Network (WUN) Education
group) and jointly submit a systematic review of
smoking prevention and cessation interventions using
school-based approaches
▸ We will incorporate the learning from this project
into health promotion lectures for Master students of
Public Health.
Non-academic audiences
There are several non-academic audiences that we wish
to reach. These include the following:
▸ The WHO Tobacco Free Initiative is part of the
Non-communicable Diseases and Mental Health cluster
at the WHO headquarters in Geneva, Switzerland;
▸ The Tobacco section of the International Union
Against TB and Lung Diseases;
▸ The National Tobacco Control Cell (NTCC), which is
the functional arm of the Ministry of Health and Family
Welfare for tobacco control activities in Bangladesh;
▸ Bangladesh Anti-Tobacco Alliance (BATA), which
includes Non-governmental organisations (NGO)
representatives who actively work in tobacco control
activities in Bangladesh;
▸ Bangladesh’s National Curriculum & Textbook
Board;
▸ Individual schools;
▸ Local leaders and community representatives;
▸ Policymakers, ward commissioners and the Upazila
Chairman who have an interest and also the responsi-
bilities to address health inequalities and the health
needs of communities;
▸ Health and social care professionals.
Ways of engagement
▸ We will establish a study Technical Working Group
(TWG). This will comprise researchers, policymakers
and representatives of the Tobacco Control Cell,
BATA, schoolteachers and community members
▸ At all stages of the project, we will carry out meet-
ings/workshops in collaboration with the National
Tobacco Control Cell. We will invite schools, other
NGO representatives, community leaders and com-
munity members in these workshops. The objective
will be to raise awareness about the smoking related
issues and explore ways of engaging with schools in
health promoting and research activities
▸ We will produce a written report and a policy brief of
research process and results
▸ We will also disseminate our research ﬁndings in
national and international conferences/seminars
▸ We will also use opportunities like World No Tobacco
Day, World TB Day to publicise our work by distributing
leaﬂets and project briefs and doing community talks
Authorship eligibility guidelines
The success of the study depends on the collaboration
of all participants. For this reason, credit for the main
results will be given to all those who have collaborated
through authorship and contribution.
Uniform requirements for authorship for manuscripts
submitted to medical journals will guide authorship
decisions. These state that authorship credit should be
based only on substantial contribution to:
1. Conception and design, or acquisition of data, or
analysis and interpretation of data;
2. Drafting the article or revising it critically for import-
ant intellectual content;
3. Final approval of the version to be published;
4. That all these conditions must be met.
Seen in this light, the chief investigator,
co-investigators, principal investigator (Bangladesh) and
the trial manager will be named as authors in any publi-
cation if they satisfy the above criteria. In addition, all
collaborators will be listed as contributors for the main
trial publication, giving details of roles in planning, con-
ducting and reporting the trial.
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